TOP NEWS
PATENTS
Merck Shakes Off Some Claims From Cholesterol Drugs Suit
By Elliot Weld
A New Jersey federal judge has partly granted a request from Merck & Co. to dismiss claims brought by Humana over an alleged anticompetitive scheme to control distribution of cholesterol drugs Zetia and Vytorin, tossing several proposed theories of monopolization but allowing unjust enrichment claims and state law antitrust claims to survive.
Opinion attached |
Read full article »
| Save to favorites »
UK Litigation Roundup: Here's What You Missed In London
By Max Austin
This past week in London has seen professional boxing promoter Boxxer take action against the former head of boxing at Matchroom Sport, Aegis Motor Insurance and Chubb European Group clash over a reinsurance claim, and a transgender pool player sue the English Blackball Pool Federation over its decision to ban her competing in women's teams and tournaments.
Read full article »
| Save to favorites »
COPYRIGHTS & TRADEMARKS
Temu Hit With $2M Penalty In FTC's 1st INFORM Act Case
By Allison Grande
The operator of Chinese e-commerce platform Temu has agreed to pay $2 million to resolve the Federal Trade Commission's inaugural enforcement action under the INFORM Consumers Act, which requires online marketplaces to provide customers with certain information and tools to combat counterfeit goods offered by high-volume third-party sellers.
2 documents attached |
Read full article »
| Save to favorites »
RIGHTS OF PUBLICITY
EXPERT ANALYSIS
LEGAL INDUSTRY
Dems Again Ask NY Ethics Body To Investigate Bove
By Jack Karp
Two Democratic senators filed an updated ethics complaint with the New York State Courts' attorney ethics body against recently confirmed Third Circuit Judge Emil Bove, citing what they called his "quid pro quo deal" to drop criminal charges against New York City Mayor Eric Adams and other alleged ethical violations.
Letter attached |
Read full article »
| Save to favorites »
Catching Up With Delaware's Chancery Court
By Sydney Price and Jeff Montgomery
Last week at the Delaware Court of Chancery, a bankruptcy administrator for a generic drugmaker formerly known as Teligent was told he can proceed with duty of oversight claims against most former officers and directors of the company, who the administrator said was complicit in the company's collapse. In an opinion, the Court of Chancery cites its 1996 decision In re Caremark International Inc. Derivative Litigation, which refined director duties of care and oversight.
Read full article »
| Save to favorites »
|